Recently, therapy with PEGylated-IL-10 and anti-PD-1 monoclonal antibody (pembrolizumab or nivolumab) has shown encouraging results in a phase 1b clinical trial conducted on advanced refractory renal cell carcinoma and non-small-cell carcinoma patients (200). Here, IL10 is linked to hereditary clear cell renal cell carcinoma.